The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling

Gynecological Endocrinology

Volumn 31, Issue 2, 2015, Pages 160-164

  Von Wahlde, Marie Kristin ^a   Hülsewig, Carolin ^a   Ruckert, Christian ^b   Götte, Martin ^a   Kiesel, Ludwig ^a   Bernemann, Christof ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Androgen receptor signaling; Chemosensitivity; Dutasteride; SRD5A 1; Triple negative breast cancer

Indexed keywords

CISPLATIN; DUTASTERIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PACLITAXEL; STEROID 5ALPHA REDUCTASE; VASCULOTROPIN; ANTIANDROGEN; ANTINEOPLASTIC AGENT; AZASTEROID; HIF1A PROTEIN, HUMAN; MEMBRANE PROTEIN; SRD5A1 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANDROGEN METABOLISM; ARTICLE; BREAST CANCER CELL LINE; CANCER CHEMOTHERAPY; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; METABOLISM; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; AZASTEROIDS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MEMBRANE PROTEINS; PACLITAXEL; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84921411055     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2014.971235     Document Type: Article

References (18)

1. Carey L, Winer E, Viale G, et al. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 2010;7: 683-92.
2. Gluz O, Liedtke C, Gottschalk N, et al. Triple-negative breast cancer - current status and future directions. Ann Oncol 2009; 20: 1913-27.
3. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
4. Yamamoto Y, Iwase H. Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol 2010;15: 341-51.
5. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
6. Liedtke C, Yan K, Wu Y, et al. Targeting of breast cancer with nononcology drugs - possible novel therapeutic option for triplenegative breast cancer. San Antonio Breast Cancer Symposium (SABCS). Cancer Res 2009;69: Abstract nr 2119.
7. Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006;24:4236-44.
8. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27.
9. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
10. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
11. Lauss M, Kriegner A, Vierlinger K, Noehammer C. Characterization of the drugged human genome. Pharmacogenomics 2007;8: 1063-73.
12. Ku JH, Shin JK, Cho MC, et al. Effect of dutasteride on the expression of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and microvessel density in rat and human prostate tissue. Scand J Urol Nephrol 2009;43:445-53.
13. Flamant L, Notte A, Ninane N, et al. Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia. Mol Cancer 2010;9:191.
14. Lazier CB, Thomas LN, Douglas RC, et al. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate 2004;58: 130-44.
15. Das K, Lorena PD, Ng LK, et al. Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer. Endocr Relat Cancer 2010;17:757-70.
16. Schmidt LJ, Murillo H, Tindall DJ. Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasteride. J Androl 2004;25:944-53.
17. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
18. Mimeault M, Batra SK. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med 2013;17: 30-54.